NEW YORK, December 30, 2025, 2:26 PM ET — Regular session
- Vera Therapeutics shares fell about 3.4% in afternoon trading, underperforming the broader market.
- Biotech ETFs were lower, keeping pressure on high-volatility drug developers into year-end.
- Investors remain focused on the FDA review path for atacicept, Vera’s lead IgA nephropathy program.
Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year.
The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease.
Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum.
Minutes from the Federal Reserve’s December meeting released on Tuesday underscored how closely investors are watching the policy debate, a backdrop that can weigh on long-duration growth stocks such as biotech.
There were no new company announcements during the session that immediately explained the drop. Shares traded between $50.45 and $53.13.
The SPDR S&P Biotech ETF was down about 1.4% and the iShares Nasdaq Biotechnology ETF fell about 1.1%, while the broad-market SPDR S&P 500 ETF and Invesco QQQ were little changed.
Rival Travere Therapeutics, which sells an FDA-approved treatment for IgA nephropathy, fell about 3.4%, tracking the risk-off tone in kidney-focused biotech names.
Vera’s investment case centers on atacicept, an experimental drug for IgA nephropathy — a progressive autoimmune kidney disease — after the company said it submitted a biologics license application, or BLA, to the FDA under the agency’s accelerated approval pathway. A BLA is the application companies file to sell a biologic medicine in the United States.
“The submission of our first BLA marks an inflection point in our journey as a company,” Chief Executive Marshall Fordyce said in a statement. GlobeNewswire
Vera said the filing was supported by interim Phase 3 data showing a reduction in proteinuria — excess protein in urine, a common marker of kidney damage — a surrogate endpoint often used in accelerated approval filings.
The company also raised fresh capital this month, pricing a public offering of Class A common stock in early December, as investors looked ahead to potential commercialization spending tied to an approval push.
Competition in IgA nephropathy has tightened after the FDA approved Otsuka’s Voyxact for reducing proteinuria in adults with the disease, Reuters reported, setting a higher bar for new entrants and putting a brighter spotlight on confirmatory data that measures longer-term kidney function.
What investors are watching next is straightforward: any FDA update that clarifies the review timeline for atacicept and the next clinical catalysts that could support a broader label. Vera has said it expects initial results from its PIONEER Phase 2 basket trial in the fourth quarter of 2025 and sees the potential for FDA approval and a U.S. launch in 2026.
From a trading perspective, shares remain below their recent highs and above their year-to-date lows, leaving $50 as a near-term level investors will watch for support as 2025 trading winds down. The stock’s 52-week range is roughly $18.53 to $56.05, according to Investing.com data.
